Delivery Order SPE2DB22D3016-SPE2DB25FBHV8
- Not listed
- The Defense Logistics Agency awarded a $1,638.00 delivery order to AmerisourceBergen Drug Corp for Copaxone 40 mg/ml syringes, with a completion date of September 10, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency awarded a $2,718.36 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Copaxone 40 mg/ml syringes, with completion scheduled for September 15, 2025. This non-set-aside contract represents a competitively awarded delivery order issued under AmerisourceBergen's broader pharmaceutical supply vehicle with DLA. The product will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child...
- The Defense Logistics Agency awarded a delivery order valued at $2,989.35 to AmerisourceBergen Drug Corp for Copaxone 40 mg/ml syringes, with completion scheduled for July 22, 2025. This non-set-aside, competitively awarded contract reflects a firm fixed price arrangement typical of pharmaceutical procurement through the federal medical supply chain. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for...
- AmerisourceBergen Drug Corp was awarded a delivery order for Copaxone 40 mg/ml syringes valued at $1,041.36 by the Defense Logistics Agency's Medical Supply Chain on August 19, 2025. This competitive, firm fixed-price contract has an ultimate completion date of August 20, 2025, and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, which is valued at $999,999,999 and extends through December 2026. The pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $2,580.20 to AmerisourceBergen Drug Corp for the supply of Copaxone 40 mg/ml syringes. The contract, issued on July 25, 2025, with an ultimate completion date of July 28, 2025, utilizes firm fixed price terms and was competitively awarded without set-aside provisions. AmerisourceBergen's Corporate Office, located in Conshohocken, Pennsylvania, serves as the place of performance for this delivery order. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $10,510.43 to AmerisourceBergen Drug Corp for the supply of Copaxone 20 mg/ml syringes. The contract, issued on August 18, 2025, with an ultimate completion date of August 19, 2025, carries firm fixed pricing with no set-aside designation, indicating competitive award status. Performance will occur at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order represents a child contract executed...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Copaxone 40 mg/ml syringes, valued at $1,971.90 with a firm fixed price structure. The order was competitively awarded without set-aside provisions and is scheduled for completion by September 11, 2025. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this requirement from its corporate office location. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Copaxone 40 mg/mL syringes under a firm fixed-price contract with a ceiling value of $1,128.54. This non-set-aside award was issued on September 2, 2025, with an ultimate completion date of September 3, 2025, and represents a direct delivery order fulfillment. The place of performance is located in Conshohocken, Pennsylvania, the company's corporate headquarters. AmerisourceBergen Drug Corp, a major...
- The Defense Logistics Agency awarded a $5,051.58 delivery order to AmerisourceBergen Drug Corp for COPAXONE 20 mg/ml syringes, with an ultimate completion date of September 15, 2025. This is a firm fixed price, non-set-aside contract issued on September 12, 2025, with performance at the contractor's Conshohocken, Pennsylvania facility. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting military and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Copaxone 40 mg/ml syringes under a firm fixed-price contract valued at $7,950.72. This is a non-set-aside competitive award with an ultimate completion date of August 26, 2025, and performance will be executed at the contractor's facility in Conshohocken, Pennsylvania. Copaxone is a disease-modifying therapy used in the treatment of multiple sclerosis, and this delivery...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FBHV8Delivery Order
The Defense Logistics Agency awarded a $1,092.00 firm fixed price delivery order to AmerisourceBergen Drug Corp for Copaxone 40 mg/ml syringes, with a completion date of September 11, 2025. This non-set-aside competitive award represents a single delivery order issued under AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement across the Defense Health System and other government healthcare organizations. This delivery order falls under AmerisourceBergen's larger $999,999,999.00 Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, which runs through December 2026 and functions as a comprehensive global pharmaceutical support vehicle. The contract enables AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. The Copaxone delivery aligns with the company's extensive portfolio of neurological and specialty pharmaceutical treatments supplied to federal health systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 9/10/25 |